Publications

Publications

Filter Results: (1,253) Arrow Down
Filter Results: (1,253) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 23 of 1,253 Results →

    Paul A. Gompers

    Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details
    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • 10 Oct 2007
    • First Look

    First Look: First Look: October 10

    Hamermesh, Faculty Chair of the Harvard Business Healthcare Initiative, discuss the barriers to personalized medicine and suggest ways to overcome them. The blockbuster model for developing drugs, the authors point out, is still what most major View Details
    Keywords: Martha Lagace

      Joshua D. Margolis

      Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • March 2023 (Revised March 2025)
      • Case

      Close Concerns: Diabetes Research and Advocacy

      By: Regina Herzlinger and Brian L. Walker
      Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details
      Keywords: Diabetes; Health; Health Care; Health Care And Treatment; Health Care Outcomes; Health Care Industry; Knowledge Dissemination; Outcome or Result; Equality and Inequality; Business Model; Entrepreneurship
      Related
      • May 2023 (Revised June 2023)
      • Case

      Novartis (A): Reimagining Medicine

      By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
      This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
      Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
      Related
      • July 2023
      • Case

      HealthVerity: Real World Data and Evidence

      By: Satish Tadikonda
      Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
      Keywords: Growth and Development Strategy; Market Entry and Exit; Product Marketing
      Related
      • December 2018
      • Case

      Corporate Transformation at Merck KGaA, Darmstadt, Germany

      By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
      When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
      Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
      Related
      • 20 Nov 2007
      • First Look

      First Look: November 20, 2007

      discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
      Keywords: Martha Lagace
      • 16 May 2023
      • HBS Case

      How KKR Got More by Giving Ownership to the Factory Floor: ‘My Kids Are Going to College!’

      pharmaceuticals and technology. Rouen cautions that the model works best in fast-growing companies, where employees can receive a sizeable payout, and in situations where a sale in the not-too-distant future can translate into wealth.... View Details
      Keywords: by Avery Forman

        Krishna G. Palepu

        KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean at the... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • 02 Aug 2011
        • First Look

        First Look: August 2

        pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
        Keywords: Sean Silverthorne

          Rohit Deshpande

          Rohit Deshpandé is a Baker Foundation Professor and Sebastian S. Kresge Professor of Marketing, Emeritus at Harvard Business School, where he has been teaching in the Advanced Management Program,... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

            Malcolm P. Baker

            Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.

            His research is in the... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • 11 Apr 2024
            • In Practice

            Why Progress on Immigration Might Soften Labor Pains

            innovation outcomes, and in many ways. Here are three: Knowledge is shared and then recombined. Knowledge is transferred from the home countries of the migrants to the US, we found in a study we did with data from US pharmaceutical... View Details
            Keywords: by Rachel Layne

              Nitin Nohria

              Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

              As Dean, building on... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                Strength in Numbers: The Political Power of Weak Interests

                Many consumers feel powerless in the face of big industry’s interests. And the dominant view of economic regulators (influenced by Mancur Olson’s book The Logic of Collective Action, published in 1965) agrees with them. According to this... View Details

                • 31 Jan 2007
                • Working Paper Summaries

                Behavioral Decision Research, Legislation, and Society: Three Cases

                Keywords: by Max H. Bazerman
                • 21 Feb 2018
                • Research & Ideas

                When a Competitor Abandons the Market, Should You Advance or Retreat?

                Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
                Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical
                • Web

                Organizational Behavior - Faculty & Research

                a corporate management revolution. Would DSO redefine leadership, or prove a cautionary tale? Keywords: Human Resources ; Business Strategy ; Alignment ; Agriculture and Agribusiness Industry ; Pharmaceutical Industry Citation Educators... View Details
                • Web

                Employment Data Trends

                Employment Data Trends Employment Data Trends Trends Career Data Internship Data Trends by Industry 2020 2021 2022 2023 2024 Consulting 24% 23% 26% 25% 18% Consumer Products 3% 3% 3% 4% 3% Entertainment / Media 2% 3% 3% 1% 3% Health Care 7% 6% 5% 5% 6% Biomed / View Details